Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track

Cartesian Therapeutics, Inc.

2025-Q1 EPS reported -$0.68 revenue$1,100,000

Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.
Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.
Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.
Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000084
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.332744+00:00
generated_at: 2026-05-22T03:51:05.827883+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000084
json_url: https://secwatch.observer/filing/0001453687-25-000084.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000084.md
text_url: https://secwatch.observer/filing/0001453687-25-000084.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/0001453687-25-000084-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/rnac-20250508.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000084

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.